Refine by
Preclinical Data Suppliers Near Mongolia
46 companies found
based inLa Jolla, CALIFORNIA (USA)
Ankasa is developing ART352-L as a novel regenerative medicine. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of ...
based inLawrence, KANSAS (USA)
Pinnacle specializes in providing reliable, robust turn-key solutions for neurophysiology research. We are always striving to bring you new and innovative tools that simplify measurement, reduce cost, and enable new discoveries. Pinnacle Technology ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
ALG.APV-527 is a bispecific antibody candidate targeting 4-1BB x 5T4 and is intended for tumor-directed treatment of solid cancers. It was built using Aptevo’s ADAPTIR™ bispecific technology platform and combines binding domains sourced ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
ADCs are not one-size-fits-all. The Dolasynthen platform enables an iterative approach to develop the right ADC for a given indication through customization and optimization. Dolasynthen utilizes a synthetic scaffold for precise control of DAR (from ...
based inBoston, MASSACHUSETTS (USA)
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...
AV-380 is AVEO’s first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in ...
based inPhiladelphia, PENNSYLVANIA (USA)
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases Cabaletta Bio seeks to employ its specifically targeted CAAR (Chimeric AutoAntibody Receptor) T ...
Our lead product candidate, DSG3-CAART, is being developed to treat mucosal pemphigus vulgaris (mPV), a blistering skin disease that affects mucous membranes. mPV is caused by autoantibodies that attack the cell adhesion protein desmoglein 3, or ...
based inHeidelberg, GERMANY
We are a team of passionate, experienced individuals who work every day to improve the lives of patients. Led by an expert team of biotechnology and pharmaceutical professionals, we are united by one goal—to stop cancer from ever derailing patients’ ...
AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing. ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
TILs are part of the body’s natural response to cancer:The cells of the immune system perform immunosurveillance while circulating throughout the bodyAs part of the normal immune response, TIL migrate to the tumor site through recognition of ...
based inAlpharetta, GEORGIA (US) (USA)
Clearside Biomedical is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). The platform provides an in-office, repeatable, non-surgical procedure, offering targeted ...
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal use. Axitinib is a tyrosine kinase inhibitor (TKI) currently approved to treat renal cell cancer that achieves pan-VEGF blockade, directly inhibiting ...
based inPak Shek Kok, HONG KONG
Artificial intelligence for every step of pharmaceutical research and development. Our mission is to accelerate drug discovery and drug development by continuously inventing and deploying new artificial intelligence technologies. We provide AI ...
based inRedwood City, CALIFORNIA (USA)
Meissa Vaccines was founded with a mission to protect people everywhere from deadly respiratory viruses and a commitment to develop innovative technologies capable of delivering effective vaccines at a global scale. Meissa is developing live ...
Meissa is developing a live attenuated COVID-19 vaccine candidate, MV-014-212, to induce mucosal and systemic immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. Like Meissa’s RSV vaccine candidate, MV-014-212 ...
based inStockholm, SWEDEN
Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd and the oral regenerative and immunomodulatory therapeutic ...
based inNorwich, UNITED KINGDOM
We are a passionate and skilled drug discovery and development biotech team developing an innovative new class of oligonucleotide antimicrobial agents. Procarta is currently working on lead optimisation for its first product, a narrow-spectrum agent ...
Proprietary nanoparticles deliver an oligonucleotide inside the bacterial pathogen. The oligonucleotide acts as a Transcription Factor Decoy (TFD): it contains the binding site of a transcription factor that controls a large set of genes required ...
based inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. ...
based inOxford, UNITED KINGDOM
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help ...
Pharmacokinetic (PK) & Pharmacodynamic (PD) modelling is often an integral component in the drug development process. PK involves studying the movement of a certain drug dose in the body. PD involves studying how a certain drug dose affects the ...
based inIssoire, FRANCE
An allogeneic platform designed to generate first in class immune therapy with the goal of harnessing the patient immune system and preventing resistance to cancer treatment. Our mission at Brenus is to provide a solution to cold solid tumors – ...
An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer ...
based inNaarden, NETHERLANDS
Azafaros has leveraged on decades of discovery by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and the Academic Medical Center in the Netherlands. Expanding on their research and led by highly experienced ...
Azafaros B.V. is pioneering the development of innovative oral small molecule compounds addressing the pathological effects of metabolite accumulation in rare metabolic disorders. Their lead compound, nizubaglustat, leverages unique dual-mode ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the ...
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
Revascor is a Phase 3 product candidate being developed as a treatment for both advanced and end-stage chronic heart failure ...